Novel Targets in Head and Neck Cancer: Should We Be Optimistic?

Gabriel Krigsfeld\textsuperscript{1} and Christine H. Chung\textsuperscript{1,2}

\textsuperscript{1}Department of Oncology and \textsuperscript{2}Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland

**Corresponding Author:** Christine H. Chung, Department of Oncology and Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, 1650 Orleans Street, CRB-1 Room 344, Baltimore, MD 21287-0013. Phone: 410-614-6204; Fax: 410-502-0677; E-mail: chung11@jhmi.edu

**Running Title:** Novel Therapeutic Targets in HNC

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.
Head and neck squamous cell carcinomas have distinct mutation and copy number profiles depending on human papillomavirus status. Although several challenges remain in biomarker implementation and clinical trial feasibility, incorporating available genomic data will expedite the development of novel therapeutics and predictive biomarker-driven clinical trials.
In this issue of *Clinical Cancer Research*, Seiwert and colleagues report mutation and copy number variation (CNV) analyses in 617 cancer-associated genes from 120 tumor-normal tissue pairs from head and neck squamous cell carcinoma (HNSCC) patients (1). They confirmed the presence of frequent mutations and CNVs in HNSCC and identified additional mutations differentially associated with human papillomavirus (HPV)-positive (+) tumors that were previously thought to be rare in HNSCCs. Further characterization of these mutational profiles may assist novel biomarker characterization and targeted therapeutic development benefiting HPV(+) and HPV-negative (−) patients.

The most common risk factors for HNSCC development are heavy tobacco use and alcohol consumption, as well as HPV infection (2, 3). HPV(+) and HPV(-) HNSCCs differ substantially in both epidemiology and clinical outcome. More specifically, HPV(+) patients have improved overall survival after initial diagnosis or following recurrent/metastatic disease (4, 5). Consistent with these notable clinical differences, recent comprehensive genetic analyses have revealed that the genetic landscapes of HPV(+) and (-) HNSCC differ greatly. There are three large genomic data sets available to date that evaluate these genetic variations using whole exome (WES) or whole genome sequencing (WGS) (6-9). However, earlier studies were dominated by HPV(-) samples, limiting the effective characterization HPV(+) tumors.

Building upon these previous studies, Seiwert and colleagues report three distinct findings; 1) HPV(+) and (-) tumors have a different profile of oncogenic mutations/CNVs, 2) HPV(+) tumors have frequent oncogene mutations previously described as rare in HNSCC, and 3) no significant difference is evident in the frequency
of mutations between HPV(+) and HPV(-) tumors. These findings may have resulted from several key differences with previous three studies. First, HPV status was balanced between the two cohorts with HPV(+) tumors representing 42.5% of total tumor samples. Across the previous studies, HPV(+) tumors accounted for only ~13% of the samples. Secondly, tissue and clinical data collection occurred at a single institution for all samples included in the study. Additionally, concurrent chemoradiation was uniformly administered across all patients in the study (1, 6-9). Furthermore, utilizing a targeted sequencing approach increases the sensitivity for detecting somatic mutations in genes of interest rather than genome wide studies designed to maximize coverage (1). Exomic or genomic deep sequencing is time-consuming, labor intensive, informatically challenging, and relatively expensive. To avoid these issues, Seiwert, et al. opted for a targeted approach investigating 617 cancer specific genes to provide a sequencing depth nearly twice that of the Cancer Genome Atlas (TCGA) (6-9). Consequently, somatic mutations present at low allelic frequencies may have been missed in the previous studies due to insufficient coverage depth.

Identification of HPV-specific mutation profiles has far-reaching clinical implications as they represent potential therapeutic targets and predictive biomarkers. Currently, we rely on prognostic biomarkers (such as HPV-status) that are associated with outcome regardless of the treatment provided. If we intend to improve patient outcomes, a shift towards predictive biomarker-driven clinical trials must be undertaken to maximize clinical benefits. The most successful predictive biomarkers in recent years are activated oncogenes. These are commonly point mutations, such as c-Kit in gastrointestinal stromal tumors; however, copy number gain and gene upregulation,
such as HER2 amplification in breast cancer, also represent powerful biomarkers. Based on current genome-wide sequencing and copy number data, several oncogenes in HNSCC are immediately targetable with agents in clinical development (Fig. 1). Current data suggest the frequency of oncogene mutations is relatively higher in HPV(+) compared to HPV(-) tumors, and the oncogene profiles differ based on the HPV status. For example, \textit{EGFR}, \textit{CCND1} and \textit{FGFR1} amplifications are more common in HPV(-) tumors while \textit{FGFR2/3} mutations are more common in HPV(+) tumors.

Currently, there are concerted efforts to conduct predictive biomarker driven clinical trials using targeted agents incorporating genomic, therapeutic, and clinical trial data in order to achieve the ultimate goal of personalized medicine. Because selecting patients with specific mutations results in small, fractionated cohorts, the use of site-specific phase II/III trials is no longer feasible. Consequently, novel designs are required such as multi-arm trials enrolling patients with a specific mutation in one of many simultaneous arms with a given targeted agent (also called umbrella, bucket, or basket trials). There are several multiple arm clinical trials currently underway, and HNSCC patients will be able to participate in the Molecular Analysis for Therapy Choice (MATCH) trial. In this study, patients with recurrent/metastatic cancers (regardless of organ site) will undergo pre- and post-treatment biopsies to sequence 200 pre-selected targetable genes in order to match with one of the ~25 targeted agents evaluated in the trial.

Although this technology is promising, significant challenges are inherent to mutational biomarker data. For example, previous studies suggested HPV(+) tumors have fewer mutations than HPV(-) tumors, while the current study failed to demonstrate
this difference. This result suggests that mutations in HPV(+) tumors (including clinically relevant mutations) may be present at lower allelic frequencies than is observed in HPV(-) tumors, requiring increased sequencing depth to detect these key differences. If validated, this finding would help establish the ideal depth of coverage for routine mutation testing to be utilized for effective biomarker detection. To date, the threshold of cancer cells harboring a targetable mutation that is required for a clinically meaningful response is unknown. If we follow the current Response Evaluation Criteria In Solid Tumors (RECIST) criteria, an activating mutation may be required to occur at cancer cell fraction greater than 0.3 (corresponding to approximately >30% of tumor mass) to observe a positive therapeutic response. For the amplified genes, the threshold of copy number gain to consider significant is again unknown in HNSCC.

Accurate mutational and CNV detection aside, the therapeutic agents matched to these targets must be effective at inhibiting oncoprotein. There is significant variability even within the same class of targeted agents with respect to efficacy and toxicity. Additional issues include determining the most clinically significant oncogene in a landscape of aberrations, the emergence of resistant clones from heterogeneous tumors, obtaining tumors for testing from inaccessible anatomic locations, and access to drugs still in developmental pipeline in cases of trial ineligible patients. For HPV(-) patients, more creative approaches to target tumor suppressor loss or the relevant downstream consequences of negative regulator loss must be improved. Furthermore, while early therapeutic response can be assessed in multi-arm trials agnostic to disease site, confirmatory trials in patients with newly diagnosed or recurrent/metastatic HNSCC with survival benefit as the primary end point will be required. In the confirmatory trials,
separate cohorts based on HPV status should be investigated, thus HNSCC provides significant, but not prohibitory challenges in future agent evaluation and trial feasibility. In conclusion, effectively incorporating sequencing data into the clinic will allow us to move beyond HPV status as our sole prognostic biomarker and necessitate novel clinical trial design and validation of biomarkers. However, the quest for personalized medicine will be easier when a comprehensive map of HNSCC is created which accurately encompasses the full breadth of heterogeneity provided by this challenging disease. We remain cautiously optimistic that we will be able to take advantage of this and future genomic studies to meaningfully benefit our patients.

References


Figure 1. Therapeutic agents that are either FDA-approved or currently in clinical trials targeting the genetic aberrations found in HNSCC determined by Seiwert and colleagues (1). Red: oncogenes, Black: tumor suppressors, Blue box: HPV(-) tumors, Green box: HPV(+) tumors. The incidence of mutations (M) and amplifications (A) are separated by HPV status. Adapted from Seiwert et al. (1).
Figure 1:

- **EGFR (A)**: 12% Cetuximab, Erlotinib, Afatinib, Gefitinib
- **FGFR1 (A)**: 2% Dovitinib, Nintedanib
- **FGFR2/3 (M)**: 1% 16% siRNA-EphA2-DOPC
- **EPHA2 (M)**: 5% 2% Dasatinib, Bosutinib, Bafetinib, Ponatinib, KX2-391, DCC-2036
- **DDR2 (M)**: 5% 2%

- **HRAS (M)**: 3% 4%
- **KRAS (M)**: 1% 6%
- **PI3K subunits (A/M)**: 34% 35%

- **PTEN (M)**: 4% 2%
- **INPP4B (M)**: 6% 2%

- **NRAS (M)**: 1% 0%
- **Salirasib, Lonafarnib, Tipifarnib, Selumetinib, Pimasertib, MEK162**

- **AKT (A)**: 7% 5%
- **TSC1/2 (M)**: 3% 4%

- **mTOR**

- **PI3K subunits (A/M)**
  - **PX-866, NVP-BEZ235, PF-05212384**

- **NF1/2 (M)**: 4% 12%
- **RASA1 (M)**: 4% 2%

- **RASA1 (M)**: 4% 2%
- **NRAS (M)**: 1% 0%
- **Salirasib, Lonafarnib, Tipifarnib, Selumetinib, Pimasertib, MEK162**

- **NF1/2 (M)**: 4% 12%
- **RASA1 (M)**: 4% 2%
Clinical Cancer Research

Novel Targets in Head and Neck Cancer: Should We Be Optimistic?

Gabriel Krigsfeld and Christine H. Chung

Clin Cancer Res Published OnlineFirst October 9, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-1776

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.